Myocardial Infarction Market Outlook 2032 | Insights Into the Evolving Market, Growth Opportunities, Epidemiology, Therapies, Treatment Algorithm, Companies

Myocardial Infarction Market Outlook 2032 | Insights Into the Evolving Market, Growth Opportunities, Epidemiology, Therapies, Treatment Algorithm, Companies
Myocardial Infarction Market
The Myocardial Infarction market research report provides current treatment practices, Myocardial Infarction emerging drugs, and Myocardial Infarction market share of the individual therapies, current and forecasted 7MM Myocardial Infarction market size from 2019 to 2032. The report also covers current Myocardial Infarction treatment practice/algorithm and Myocardial Infarction unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Myocardial Infarction Market landscape is undergoing transformation, propelled by the recent introduction of Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) inhibitors, which are lipid-lowering therapies. Anticipated launches of upcoming therapies, coupled with increased emphasis on early patient screening and medication administration in secondary care and other clinical settings, alongside a heightened awareness, are poised to fuel market expansion in the foreseeable future.

Some of the key players such as Novartis (pelacarsen), Recardio (dutogliptin), Idorsia Pharmaceuticals (selatogrel), Boehringer Ingelheim and Eli Lilly and Company (JARDIANCE), Amgen (olpasiran), Mitsubishi Chemical Group (CL2020), and others are evaluating their lead candidates in different stages of clinical development.

DelveInsight’s “Myocardial Infarction Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Myocardial Infarction market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Myocardial Infarction market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Myocardial Infarction Overview

A myocardial infarction, commonly known as a heart attack, occurs when blood flow decreases or stops in one of the coronary arteries of the heart, causing infarction (tissue death) to the heart muscle. The most common symptom is chest pain or discomfort, which may radiate into the shoulder, arm, back, neck, or jaw. This pain often occurs in the center or left side of the chest and lasts for more than a few minutes. Sometimes, the discomfort may resemble heartburn. Other symptoms can include shortness of breath, nausea, feeling faint, cold sweat, tiredness, and a decreased level of consciousness. Approximately 30% of people experience atypical symptoms, and women may present without chest pain, instead experiencing neck pain, arm pain, or fatigue. In older individuals over 75 years old, about 5% have had an MI with little or no history of symptoms1. An MI can lead to complications such as heart failure, irregular heartbeat, cardiogenic shock, or even cardiac arrest.

The underlying mechanism of an MI is usually the complete blockage of a coronary artery caused by the rupture of an atherosclerotic plaque. Risk factors for MI include high blood pressure, smoking, diabetes, lack of exercise, obesity, high blood cholesterol, poor diet, and excessive alcohol intake. Less commonly, MIs can be caused by coronary artery spasms due to factors like cocaine use, extreme emotional stress (known as Takotsubo syndrome or broken heart syndrome), or exposure to extreme cold.

Myocardial Infarction Market Key Facts

  • The total Myocardial Infarction market size in the 7MM is USD 21,477 million in 2021 and is projected to increase during the forecast period.
  • The Myocardial Infarction market in 7MM will increase at a CAGR of 1.61% due to increasing awareness of the disease and the launch of the emerging therapy
  • Among EU4 countries, Germany accounts for the maximum market size in 2021, while Spain occupied the bottom of the ladder in 2021
  • The total Myocardial Infarction diagnosed prevalent cases in the 7MM were approximately 15 million in 2021 and are projected to increase during the forecasted period.
  • The total diagnosed prevalent cases of Myocardial Infarction in the United States were around 8 million in 2021.
  • The United States contributed to the largest prevalent population of MI, acquiring ~52% of the 7MM in 2021. Whereas EU4 and the UK, and Japan accounted for around 36% and 11% of the total population share, respectively, in 2021
  • Among the EU4 countries, Germany accounted for the largest number of diagnosed Myocardial Infarction cases, followed by France, whereas Spain accounted for the lowest number of cases in 2021

Myocardial Infarction Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Myocardial Infarction market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Myocardial Infarction market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.

Myocardial Infarction Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders. 

Myocardial Infarction Drugs Uptake and Pipeline Development Activities

The drugs’ uptake section focuses on the rate of uptake of the potential drugs recently launched in the Myocardial Infarction market or expected to get launched during the study period. The analysis covers the Myocardial Infarction market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Myocardial Infarction pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Myocardial Infarction Market Will Evolve and Grow by 2032 @

Leading Companies in the Myocardial Infarction Therapeutics Market Include:

  • AstraZeneca
  • Boehringer Ingelheim
  • Eli Lilly and Company
  • Amgen
  • Novartis
  • Idorsia Pharmaceuticals
  • Faraday Pharmaceuticals
  • CSL Behring
  • Immediate Therapeutics
  • Mitsubishi Chemical Group
  • Kancera
  • Bayer
  • Recardio
  • Mesoblast
  • And Many Others

Myocardial Infarction Therapies Covered in the Report Include:

  • FARXIGA/FORXIGA (dapagliflozin): AstraZeneca
  • JARDIANCE (empagliflozin): Boehringer Ingelheim and Eli Lilly and Company
  • Olpasiran: Amgen
  • INSPRA (eplerenone): Pfizer
  • PLAVIX (clopidogrel bisulfate): Sanofi-Aventis/Bristol-Myers Squibb
  • BRILINTA (ticagrelor): AstraZeneca
  • PRALUENT (alirocumab): Regeneron/Sanofi
  • And Many Others

Download the Sample Report to Learn More @

Table of Content

1. Key Insights

2. Executive Summary 

3. Myocardial Infarction Competitive Intelligence Analysis

4. Myocardial Infarction Market Overview at a Glance

5. Myocardial Infarction Disease Background and Overview

6. Myocardial Infarction Patient Journey

7. Myocardial Infarction Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Myocardial Infarction Treatment Algorithm, Current Treatment, and Medical Practices

9. Myocardial Infarction Unmet Needs

10. Key Endpoints of Myocardial Infarction Treatment

11. Myocardial Infarction Marketed Products

12. Myocardial Infarction Emerging Drugs and Latest Therapeutic Advances

13. Myocardial Infarction Seven Major Market Analysis

14. Attribute Analysis

15. Myocardial Infarction Market Outlook (In US, EU5, and Japan)

16. Myocardial Infarction Access and Reimbursement Overview

17. KOL Views on the Myocardial Infarction Market

18. Myocardial Infarction Market Drivers

19. Myocardial Infarction Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States